🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-521316-19-00
Completed Phase IV

Optimization of pain management for acute renal colic in the Emergency Department – The OPTIMIZED trial

2025-521316-19-00 · tracked via the Priya Life Science EU tracker
Sponsor
Leids Universitair Medisch Centrum (LUMC)
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Anesthesia and Analgesia
Decision date
21/11/2025
Enrollment target
160
Sites
Netherlands

Condition studied

Urolithiasis

Investigational medicinal product(s)

ROPIVACAINESODIUM CHLORIDE

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male

Primary endpoint

To decrease pain intensity and pain interference, as measured with the Brief Pain Inventory Short Fort (BPI-SF). This is defined as the difference in scores 24 hours after the intervention between the two groups., To minimize hospitalizations and urologic interventions. This is defined as the difference in proportion of patients that required a same-day hospital admission or underwent a urologic intervention within seven days (yes/no).

Endpoint detail

A decrease in pain intensity as measured with the Numeric Rating Scale (NRS) be-tween baseline and 30 minutes, 60 minutes, six hours, twelve hours and 24 hours after the intervention (but only measured during the time the patient is awake)., Representations to the ED related to renal colic within seven days after the inter-vention, compared between both groups., Incidence of chronic pain, measured by the BPI-SF one month after the interven-tion. The definition of chronic secondary pain this study uses is “Pain that persists or recurs beyond successful treatment of the initial cause, Improvement of quality of life, measured by the EQ-5D-5L seven days and one month after the intervention, compared to baseline in both groups., Patient satisfaction, measured by Patient Global Impression of Change (PGIC) after 24 hours and seven days, compared between both groups, Reduction of use of analgesic rescue medication within the first 24 hours after the intervention, compared between both groups., Time to first analgesic rescue medication (both NSAIDs and opioids) after the inter-vention, compared between both groups., Reduction of opioid-related adverse events, measured by the Overall Benefit of Analgesia Score after 24 hours., Safety, measured as the number and type of serious adverse events (such as infection, bleeding, LAST or pneumothorax) related to the ESPB occurring within one month of the intervention., Cost-effectiveness: relating the costs of healthcare use and productivity losses related to the renal colic, measures via shortened versions of the iMTA Medical Consumption Ques-tionnaire (iMCQ) and iMTA Productivity Cost Questionnaire (iPCQ), up to one month after intervention to the quality of life

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521316-19-00 on CTIS ↗ ← All trials in the EU